AU2007328228B2 - Peptide and treatment for HIV-1 infection - Google Patents

Peptide and treatment for HIV-1 infection Download PDF

Info

Publication number
AU2007328228B2
AU2007328228B2 AU2007328228A AU2007328228A AU2007328228B2 AU 2007328228 B2 AU2007328228 B2 AU 2007328228B2 AU 2007328228 A AU2007328228 A AU 2007328228A AU 2007328228 A AU2007328228 A AU 2007328228A AU 2007328228 B2 AU2007328228 B2 AU 2007328228B2
Authority
AU
Australia
Prior art keywords
seq
compound
amino acid
peptide
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007328228A
Other languages
English (en)
Other versions
AU2007328228A1 (en
Inventor
Harold C. Smith
Hui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
OYAGEN Inc
Original Assignee
Thomas Jefferson University
OYAGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University, OYAGEN Inc filed Critical Thomas Jefferson University
Publication of AU2007328228A1 publication Critical patent/AU2007328228A1/en
Application granted granted Critical
Publication of AU2007328228B2 publication Critical patent/AU2007328228B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2007328228A 2006-12-06 2007-12-04 Peptide and treatment for HIV-1 infection Ceased AU2007328228B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87318606P 2006-12-06 2006-12-06
US60/873,186 2006-12-06
PCT/US2007/024790 WO2008070049A2 (en) 2006-12-06 2007-12-04 Peptide and treatment for hiv-1 infection

Publications (2)

Publication Number Publication Date
AU2007328228A1 AU2007328228A1 (en) 2008-06-12
AU2007328228B2 true AU2007328228B2 (en) 2012-09-20

Family

ID=39492836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007328228A Ceased AU2007328228B2 (en) 2006-12-06 2007-12-04 Peptide and treatment for HIV-1 infection

Country Status (7)

Country Link
US (1) US8334255B2 (enExample)
EP (1) EP2097090B1 (enExample)
JP (1) JP5519291B2 (enExample)
AU (1) AU2007328228B2 (enExample)
CA (1) CA2671410C (enExample)
ES (1) ES2526060T3 (enExample)
WO (1) WO2008070049A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
US10588902B2 (en) 2013-06-24 2020-03-17 Oyagen, Inc. Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association
KR20180132807A (ko) 2016-04-07 2018-12-12 케이스 웨스턴 리저브 유니버시티 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제
WO2018128993A1 (en) * 2017-01-04 2018-07-12 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653443B2 (en) * 2001-04-06 2003-11-25 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP2116604A1 (en) * 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US7125849B2 (en) * 2003-01-14 2006-10-24 The Scripps Research Institute Peptide-based angiogenesis inhibitors and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653443B2 (en) * 2001-04-06 2003-11-25 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target

Also Published As

Publication number Publication date
ES2526060T3 (es) 2015-01-05
WO2008070049A2 (en) 2008-06-12
WO2008070049A8 (en) 2008-10-30
AU2007328228A1 (en) 2008-06-12
JP5519291B2 (ja) 2014-06-11
US8334255B2 (en) 2012-12-18
WO2008070049A3 (en) 2009-01-29
EP2097090A2 (en) 2009-09-09
EP2097090A4 (en) 2012-07-11
CA2671410A1 (en) 2008-06-12
JP2010511706A (ja) 2010-04-15
US20100029570A1 (en) 2010-02-04
EP2097090B1 (en) 2014-10-29
CA2671410C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
US7498138B2 (en) Multimerization of HIV-1 Vif protein as a therapeutic target
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
WO2008086042A2 (en) Preventing infection by a measles or respiratory syncytial virus
Gómara et al. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor
KR20100016142A (ko) 항바이러스 펩티드 치료제 전달용 신규 제제
RU2741123C1 (ru) Липопептид для эффективного ингибирования вич, его производное, фармацевтическая композиция и их применение
EP2097090B1 (en) Peptide and treatment for hiv-1 infection
CN1327897C (zh) Hiv感染的肽衍生物融合抑制剂
WO2001056591A1 (en) vMIP-II PEPTIDE ANTAGONISTS OF CXCR4
US11098085B2 (en) Use of a HIV derived accessory protein for the reactivation of latent HIV
US11186614B2 (en) Anti-HIV peptides
WO2012139519A1 (zh) 环肽及其医药用途
WO2025167910A1 (zh) 一种可口服的长效多肽类hiv灭活剂
US7754687B2 (en) Methods of inhibiting viral infection
WO2021156451A1 (en) C-x-c motif chemokine receptor 4 antagonist
EP3377519B1 (en) Labyrinthopeptins as anti-viral agents
CA3004805C (en) Labyrinthopeptins as anti-viral agents
WO2022023535A1 (en) Replication-deficient adenovirus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired